Clinical characteristics of study participants. All continuous numerical data are presented as median (range) unless otherwise stated. In one patient who was taking gliclazide and not glibenclamide, dose was converted to glibenclamide equivalent using % maximum dose according to British National Formulary
| Clinical feature | KCNJ11 cases | Non-diabetic controls | P value |
| Age (years) | 39.1 (24.4–41.0) | 39.6 (24.2–41.8) | 0.60 |
| Sex, male (%) | 1 (20) | 1 (20) | 1.00 |
| BMI | 22.9 (22.4–26.8) | 24.6 (23.9–25.6) | 0.60 |
| Fasting glucose (mmol/mol) | 10.1 (8.6–11.9) | 5.3 (4.8–5.5) | 0.009 |
| KCNJ11 mutation | 4 R201H, 1 R201C | N/A | N/A |
| SU dose (mg/kg/day glibenclamide) | 0.28 (0.07–1.21) | N/A | N/A |
| HbA1c (%) | 6.9 (6.5–7.9) | N/A | N/A |
| HbA1c (mmol/mol) | 52 (48–63) | N/A | N/A |
BMI, body mass index; N/A, not applicable; SU, sulfonylurea.